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A Novel FKS06- and Rapamycin-binding Protein (FPR3 
Gene Product) in the Yeast Saccharomyces revisiae 
Is a Proline Rotamase Localized to the Nucleolus 
Bret M. Benton, Ji-Hong Zang and Jeremy Thorner 
Division of Biochemistry and Molecular Biology, Department ofMolecular and Cell Biology, University of California, Berkeley, 
California 94720-3202 
Abstract. The gene (FPR3) encoding a novel type of 
peptidylprolyl-cis-trans-isomerase (PPIase) was iso- 
lated during a search for previously unidentified nu- 
clear proteins in Saccharomyces revisiae. PPIases 
are thought o act in conjunction with protein chaper- 
ones because they accelerate the rate of conforma- 
tional interconversions around proline residues in 
polypeptides. The FPR3 gene product (Fpr3) is 413 
amino acids long. The 111 COOH-terminal residues of 
Fpr3 share greater than 40% amino acid identity with 
a particular class of PPIases, termed FK506-binding 
proteins (FKBPs) because they are the intracellular 
receptors for two immunosuppressive compounds, 
rapamycin and FK506. When expressed in and purified 
from Escherichia coli, both full-length Fpr3 and its 
isolated COOH-terminal domain exhibit readily detect- 
able PPIase activity. Both fpr3A null mutants and cells 
expressing FPR3 from its own promoter on a mul- 
ticopy plasmid have no discernible growth phenotype 
and do not display any alteration in sensitivity to the 
growth-inhibitory effects of either FK506 or rapamy- 
cin. In S. cerevisiae, the gene for ~i ll2-residue cyto- 
solic FKBP (FPRI) and the gene for a 135-residue 
ER-associated FKBP (FPR2) have been described be- 
fore. Even fprl fpr2 fpr3 triple mutants are viable. 
However, in cells carrying an fprlA mutation (which 
confers resistance to rapamycin), overexpression from 
the GAL/promoter of the C-terminal domain of Fpr3, 
but not full-length Fpr3, restored sensitivity to 
rapamycin. Conversely, overproduction from the GAL/ 
promoter of full-length Fpr3, but not its COOH- 
terminal domain, is growth inhibitory in both normal 
cells and fprlA mutants. In fprlA cells, the toxic effect 
of Fpr3 overproduction can be reversed by rapamycin. 
Overproduction of the NH2-terminal domain of Fpr3 is 
also growth inhibitory in normal cells and fprlA mu- 
tants, but this toxicity is not ameliorated in fprlA cells 
by rapamycin. The NH2-terminal domain of Fpr3 con- 
tains long stretches of acidic residues alternating with 
blocks of basic residues, a structure that resembles e- 
quences found in nucleolar proteins, including S. 
cerevisiae NSRI and mammalian ucleolin. Indirect 
immunofluorescence with polyclonal antibodies raised 
against either the NH2- or the COOH-terminal seg- 
ments of Fpr3 expressed in E. coli demonstrated that 
Fpr3 is located exclusively in the nucleolus. 
QUISITION of the functional state of a polypeptide 
frequently requires the participation of other pro- 
teins which assist in and accelerate the process of 
protein folding (Gething and Sambrook, 1992; Hartl et al., 
1994). Proline rotamases, more formally peptidylprolyl- 
cis,trans-isomerases (PPIases)/ are thought o participate 
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2 % glucose; GST, Schistosomajaponicura glutathione S-transferase; HSE, 
heat shock response lement; Hsp, heat shock protein; PPIases, peptidyl- 
prolyl-cis, trans-isomerases. 
in protein folding and protein assembly events in vivo (Par- 
sell and Lindquist, 1993) because in vitro these enzymes 
catalyze interconversion of the cis and trans isomers of the 
bond between the carboxyl group of the preceding amino 
acid and the imino nitrogen of proline in peptide and protein 
substrates (Kofron et al., 1991; Stein, 1991). It was discov- 
ered several years ago that there are two separate types of 
PPIases. This realization was made possible by investiga- 
tions into the molecular mode of action of antibiotics that act 
as immunosuppressants i  humans. These drugs effectively 
block the specific signal transduction pathways required for 
activation and proliferation of T lymphocytes (for review see 
Schreiber et al., 1993). 
The first PPIase isolated (Fischer et al., 1984) was shown 
to be the intracellular eceptor for an immunosuppressant, 
cyclosporin A (CsA); and hence, a member of this class of 
PPIase is called a cyclophilin (Fischer et al., 1989; Taka- 
© The Rockefeller University Press, 0021-9525/94/11/623/17 $2.00 
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hashi et al., 1989). It was subsequently shown that an un- 
related protein, dubbed an FK506-binding protein (FKBP) 
because it serves as the intracellular receptor for two other 
immunosuppressive compounds, FK506 and rapamycin, is
also a PPIase (Harding et al., 1989; Siekierka et al., 1989). 
All three of the immunosuppressive ag nts contain within 
their structure a pipecolyl bond that mimics the X-Pro bonds 
in proteins. The binding of these drugs to their respective 
binding protiens, collectively termed "immunophilins; po- 
tently inhibits their PPIase activity. Furthermore, there is no 
cross-inhibition; FK506 and rapamycin only interact with 
FKBPs, and CsA only interacts with cyclophilins. Despite 
their common enzymic function as PPIases, the cyclophilins 
and the FKBPs do not possess any significant sequence ho- 
mology and, thus, represent two distinct, but highly con- 
served, superfamilies. Members of both families are found 
in organisms as diverse as bacteria (Hacker and Fischer, 
1993), fungi (Tropschug et al., 1988), plants (Luan et al., 
1994), insects (Shieh et al., 1989), and mammals (Schreiber, 
1991). 
CsA, FK506, and rapamycin were initially discovered be- 
cause they are cytotoxic to many types of microorganisms, 
including the yeast Saccharomyces cerevisiae (Tropschug et 
al., 1989; Heitman et al., 1991b; Koltin et al., 1991). In S. 
cerevisiae, three cyclophilin genes have been identified. The 
CYP1 product, an abundant cytosolic protein, is the cellular 
receptor that mediates CsA toxicity (Tropschug et al., 1989; 
Koser et al., 1991). The CYP2 product is a cyclophilin that 
contains a putative signal sequence and is localized in the ER 
(Koser et al., 1991). The CPR3 product encodes acyclophi- 
lin with a mitochondrial targeting sequence and is localized 
in that organelle (Davis et al., 1992). Two genes encoding 
FKBPs have been described in S. cerevisiae. FPRI (RBP1, 
FKB1) encodes a 12-kD cytosolic protein, termed FKBP-12, 
which serves as the sole receptor for rapamycin and is also 
a major site for FKS06 binding (Heitman et al., 1991a,b; 
Koltin et al., 1991; Wiederrecht e  al., 1991). FKB2 (FPR2) 
encodes an ER-associated FKBP, designated FKBP-13, 
which is apparently not involved in mediating either apamy- 
cin or FK506 toxicity (Nielsen et al., 1992). 
Several ines of evidence indicate that inhibition of the 
PPIase activity of the cyclophilins or the FKBPs is not the 
mechanism by which the drugs exert heir immunosuppres- 
sive and growth-inhibitory effects. For example, a close 
structural nalogue of FKS06, called 506BD, is able to bind 
in vitro to FKBP-12 (the major cytosolic FK506- and 
rapamycin-binding protein in human T cells) with the same 
at~nity as FKS06 and is able to inhibit its rotamase activity 
with equivalent efficacy, yet 506BD does not act as an im- 
munosuppressant (Bierer et al., 1990b). In yeast, cells car- 
rying a null mutation in the FPRI gene grow normally et 
are completely resistant to the cytotoxic effects of rapamy- 
cin, indicating that loss of Fprl activity is not deleterious and 
that, in the absence of FKBP-12, rapamycin cannot exert its 
inhibitory action (Heitman et al., 1991a,b; Koltin et al., 
1991; Wiederrecht et al., 1991). These findings suggested 
that drug binding in vivo generates a novel entity, the im- 
munophilin-drug complex, which causes its effects by inter- 
acting with another cellular target(s). 
Indeed, recent biochemical studies have demonstrated that 
both cyclophilin-CsA complex and FKBP12-FK506 com- 
plex bind to and inhibit calcineurin, a ubiquitous Ca2+/ 
calmodulin-activated phosphoprotein phosphatase (Liu et 
al., 1991; Clipstone and Crabtree, 1992; O'Keefe et al., 
1992). In T cells, calcineurin action is necessary for activa- 
tion of the transcription factor, NF-AT, which is required for 
expression of the genes for interleukin-2 and interleukin-2 
receptor (Jain et al., 1993). In yeast, FKBP12-FKS06 and 
cyclophilin-CsA also inhibit calcineurin (Foor et al., 1992). 
Although calcineurin is not required for the vegetative 
growth of yeast cells, the function of this enzyme is neces- 
sary for the maintenance of viability and the resumption of 
cell division after cells have been arrested by the action of 
mating pheromone (Cyert et al., 1991; Cyert and Thorner, 
1992). In contrast, he FKBP-rapamycin complex interdicts 
a different target. In T cells, rapamycin i terferes with the 
signal generated from the occupied interleukin-2 receptor 
(Bierer et al., 1990a; Dumont et al., 1990) and results in an 
inhibition of the phosphorylation a d activation of the 70-kD 
ribosomal protein $6 kinase (Kuo et al., 1992; Price et al., 
1992). In yeast, cellular targets of FKBP12-rapamycin ap- 
pear to be the TOR/and TOR2 gene products, a set of puta- 
tive phosphotidylinositol kinases (Flanagan et al., 1993; 
Kunz et al., 1993; Helliwell et al., 1994), which may regu- 
late, directly or indirectly, activation of p70 $6 kinase. Re- 
cent results indicate that animal cells also contain a homo- 
logue of Tor2 that is capable of associating with the 
FKBP-rapamycin complex (Brown et al., 1994; Sabatini et 
al., 1994). 
The normal functions of the PPIases are poorly under- 
stood and identification ftheir physiologically relevant sub- 
strates is minimal. There is some support for the view that 
certain PPIases may assist in the folding (or unfolding) of in- 
dividual proteins. In D. melanogaster, a mutation in the 
ninaA gene, which is expressed specifically in the retina nd 
encodes a cyclophilin anchored in the ER membrane, causes 
misfolded forms of rhodopsins (but not other proteins) to ac- 
cumulate in the ER lumen, suggesting that he ninaA product 
is required for correct folding of the rhodopsins. Other evi- 
dence indicates that PPIases may play a role in facilitating 
protein-protein teractions required for the assembly (or 
disassembly) of multi-protein complexes. For example, be- 
fore hormone administration, the glucocorticoid receptor re- 
sides in the cytosol in a large 9S complex containing two heat 
shock proteins, Hsp90 and Hsp70, and a previously uniden- 
tiffed 59-kD protein (p59) (Sanchez et al., 1990). Upon 
binding of steroid, the receptor-containing complex dissoci- 
ates, and the receptor can now dimerize and translocate o
the nucleus in a state competent tobind to its specific target 
DNA sequence (Pratt, 1987). The p59 component ofthe in- 
active receptor complex has recently been characterized and 
is a new type of FKBP apparently containing two catalytic 
domains (Ku Tai et al., 1992). Complete understanding of 
the functions of the PPIases in eukaryotic cells will require 
elucidation of the number of such enzymes present, heir lo- 
calization within the cell, and the nature of their authentic 
substrates in vivo. 
In an immunological screen to identify previously un- 
characterized nuclear proteins, we isolated the gene for an 
FKBP of unique structure. Here we describe the isolation, 
structural features, enzymic properties, and subeellular lo- 
calization of this novel member of the FKBP family. We also 
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examined the ability of this protein to interact with im- 
munosuppressant drugs and the phenotypic onsequences of
eliminating or overproducing this new FKBP in the cell. 
Materials and Methods 
Yeast Strains, Culture Conditions, 
and Genetic Techniques 
The yeast strains used in this work, and. their construction, are described 
in Table I. Unless otherwise specified, cells were grown at 30°C. Rich 
medium (YPD) and synthetic defined medium (SD), lacking one or a com- 
bination of nutrients as required for maintenance ofplasmids, were prepared 
according to Sherman et al. (1986). SD medium contained as the carbon 
source ither 2% glucose (Glc) or 2% galactose supplemented with 0.2% 
sucrose (Gal). Standard methods were used for genetic rosses, sporniation, 
and tetrad analysis (Sherman et al., 1986). DNA-mediated transformation 
was carried out using the lithium acetate method (Ito, 1983), as modified 
by Schiestl and Geitz (1989). Because of their larger size, a polyploid com- 
mercial strain of baker's yeast (Fleischmann's) was used in some of the im- 
munottuorescence experiments. 
Preparation of Anti-nuclear Protein Antibodies 
Nuclei were prepared from 41 of strain BJ2168, essentially as described by 
Aris and Blobel 0991). After exhaustive digestion with DNAse I and 
RNAse A, the remaining nuclear envelope fraction and other particulate 
material (,o3 nag total protein) were collected by centrifugation for 20 rain 
at 23,500 g in a Sorvall I-IB-4 rotor (Aris and Blobel, 1989), solubilized 
directly in 1.5 ml of SDS-PAGE sample buffer (Laemmli, 1970), subjected 
to preparative SDS-PAGE, and visualized by staining with Coomassie blue 
dye. Prominent polypeptides in this preparation were isolated by prepara- 
tive SDS-PAGE, recovered from gels using an Elutrap TM elution chamber 
(Schleicher & Schuell, Keene, Nil), and used to immunize adult female 
New Zealand white rabbits, following standard procedures (Harlow and 
Lane, 1988). Antibodies directed against amajor band that had an apparent 
molecular mass of ,,o65 kD were affinity-purified by minor modifications 
of the method of Smith and Fisher 0984). In brief, samples of the electro- 
eluted 65-kD protein were resolved by SDS-PAGE and electrophoretically 
transferred toa nitrocellulose filter (Towbin et al., 1979); the strip contain- 
ing the immobilized 65-kD band then was used as an immunoadsorbant to 
select specific antibodies from a polyelonal antiserum (no. SB126) that had 
been raised against the same antigen. 
Isolation of the FPR3 Gene and DNA 
Sequence Analysis 
A yeast genomic DNA library (girl ofR. Hamataki and A. Sugino, National 
Institute of Environmental Health Sciences, Research Triangle Park, NC) 
constructed in the bacteriophage expression vector, hgtll, was screened 
with the anti-65-kD protein antibodies immunoseleeted from antiserum no. 
SB126, using standard procedures (Snyder ct al., 1987). One candidate 
phage (LllB7) was identified by its immtmoreactivity and was isolated to 
homogeneity using four successive rounds of plaque purification and 
rescreening. Phage DNA was prepared by standard methods (Sambrook et 
al., 1989), and the insert DNA was released by digestion with EcoRI and 
subcloned into the pBluescript II KS+ vector (Stratagene Inc., La Jolla, 
CA). Nucleotide sequence analysis was performed by the dideoxy chain ter- 
mination method (Sanger et al., 1977) using the universal primers for 
pBluescript II KS+ and, where necessary, custom-synthesized oligonucleo- 
tide primers and Sequenase TM enzyme (US Biochem. Corp., Cleveland, 
OH), under conditions recommended bythe supplier. To confirm the se- 
quence of FPR3 and to obtain additional flanking sequence, the insert DNA 
from phage L11B7 was radiolabeled using the random primer method (Fein- 
berg and Vogelstein, 1984) and used to screen a plasmid library of yeast 
genomic DNA in the vector pSB32 (gift of E Spencer and P. Heiter, Johns 
Hopkins University School of Medicine, Baltimore, MD), which yielded 
plasmid pBYNGI. The entire FPR3 coding region was contained within a 
2.2-kb HindllI fragment of the genomic DNA insert in pBYNG1. This frag- 
ment was ligated into pUC19, to generate plasmid pNH2.2, and the DNA 
sequence of 1711 hp of continuous sequence from the 2.2-kb insert in 
pNH2.2 was determined on both strands, using the methods described im- 
mediately above. 
Physical and Genetic Mapping of the FPR3 Locus 
To determine the chromosomal location of FPR3, the 2.2-kb HindlII frag- 
ment from pNH2.2 was radiolabeled by the random primer method (Fein- 
berg and Vogelstein, 1984) and used for hybridization, first, to a blot (gift 
of Gary Anderson, University of California, Berkeley, CA) on which intact 
yeast chromosomes had been resolved by electrophoresis ina clamped ho- 
mogenous electric field (Vollrath ct al., 1988) and, second, to filters con- 
taining an ordered set of yeast DNA segments (gift of Linda Riles and May- 
nard Olson, Washington University School of Medicine, St. Louis, MO) 
Table L S. cerevisiae Strains 
Strain Genotype Source 
YPH499 MATa ade2-101 °~ his3-A200 leu2-A1 lys2-80P m Sikorski and Hieter, 1989 
trpl-A1 ura3-52 
MATct (otherwise isogenic to YPH499) 
MATa/MATa (otherwise isogenic to YPH499) 
MATa gal2 leu2 prbl-l122 pep4-3 prcl-407 trpl 
ura3-52 
YPH499 fpr3-Al::URA3 This Work 
YPH501 fpr3-AI::URA3/FRP3 This Work 
YPH501 fpr3-AI::URA3/fpr3-AI::URA3 This Work 
YPH500 fpr3-2::HlS3 This Work 
YPH499 fprl-2::ADE2 This Work 
YPH499 fprl-2::ADE2 fpr3-2::HlS3 This Work 
YPH501 fprl-2::ADE2/FPR1 fpr2-1::URA3/FPR2 This Work 
YPH499 f-pr2-1:URA3 This Work 
YPH499 fprl-2::ADE2 fpr2-1::URA3 This Work 
fpr3-2: HlS3 
YPH500 hmgl::LYS2 This Work 
YPHS00 
YPH501 
BJ2168 
YB100 
YB103 
YB104 
YBI05 
YB107* 
YB112 
YB168 
YB169A* 
YB171A 
YB58 
Sikorski and Hieter, 1989 
Sikorski and Hieter, 1989 
Jones, 1991 
* Thefprl-2::ADE2 insertion mutation was excised from plasmid pYJH25A as described previously (Heitman et al., 1991b) and used for DNA-mediated transfor- 
mation of YPH499 (and YPH501), selecting for Ade + transformants. Correct gene transplacement of he FPR1 locus was confirmed by restriction enzyme diges- 
tion and Southern hybridization analysis. 
Thefpr2-1::URA3 mutation was excised from plasmid pFPR2D1 on a 2.0-kb BamHI-EcoRI fragment (see Materials and Methods) and used for DNA-mediated 
transformation f YPH499 (and YPH501), selecting for Ura* transformants. Correct gene transplacement of he FPR2 locus was confirmed by restriction enzyme 
digestion and Southern hybridization analysis. 
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representative of the entire yeast genome (Link and Olson, 1991). To 
confirm the map location of FPR3 determined by physical methods, a 
genetic ross was performed between a strain (YBI00) carrying thefpr3- 
AI::URA3 allele (see below) and a strain (YB58) carrying a marker 
(hragl::LYS2) known to reside on the left arm of chromosome XIII. 
Construction of  fpr3 Null Mutations 
Thefpr3-Al::URA3 deletion mutation was constructed asfollows. A L2-kb 
URA3-containing HindIlI fragment from plasmid pJJ242 (Jones and 
Prakash, 1990) was converted toblunt ends by incubation with the Klenow 
fragment of E. coli DNA polymerase I and dNTPs, and then ligated into 
the Sinai site of pBluescript II KS+, to give plasmid pBSURA3. The 2.2-kb 
genomic Hindm fragment containing FPR3 was transferred into the HindIII 
site of pUC-RI (a derivative of pUC19 in which the EcoRI site has been 
destroyed; B.M. Benton, unpublished results), to yield plasmid pNH2.2B. 
The ClaI site that is most upstream of the FPR3 coding sequence inthe 2.2- 
kb HindllI fragment inpNH2.2B (see Fig. 1) was destroyed by partial diges- 
tion with ClaI followed by incubation with dNTPs and the Klenow fragment 
and religation, to generate plasmid pNH2.2C. Plasmid pNH2.2C was 
digested, first with ClaI, and the overhangs so generated were converted to 
blunt ends, and then with EcoR/, which removed the segment encoding 
residues 44-278 of the FPR3 coding sequence. A 1.2-kb URA3-contalning 
SmaI-EcoRI fragment excised from plasmid pBSURA3 was inserted into the 
blunt[ClaI]-EcoR/sites of pNH2.2C, yielding plasmid pFPR3D1. The lin- 
ear 2.8-kb HindlR fragment of pFPR3D1 containing the fpr3-AI::URA3 
mutation was excised by digestion with Hind111, purified by agarose gel 
electrophoresis, and introduced into YPH501 by DNA-mediated transfor- 
marion, selecting for Ura + transformants. Oene replacement (Rothstein, 
1983) of the FPR3 locus on one homologue of chromosome XRI was 
confirmed by restriction enzyme digestion and Southern hybridization a al- 
ysis (Southern, 1975) of genomic DNA isolated from the Ura + transfor- 
mants (Hoffrnan and Winston, 1987). 
To construct thefpr3-2::Hl$3 insertion mutation, a 3.3-kb BglII frag- 
ment containing the F/R3 coding sequence was excised from the genomic 
insert in pBYNG1 and ligated into the BamHI site of pBluescript II KS+ 
(Stratagene Inc.), to create plasmid pNB3.3, pNB3.3 was digested with 
NdeI, which cleaves at codon 386 of the F/R3 coding sequence, converted 
to blunt ends, and ligated to a 2.l-kb PvuII fragment that contains the HIS3 
gene, which was isolated from plasmid pJl217 (Jones and Prakash, 1990), 
to create plasmid pFPR3D2. A linear 5.8-kb PvulI fragment from 
pFPR3D2 containing thefpr3-2::HIS3 mutation was gel-purified and used 
for transformation f YPH501, selecting for His + transformants. Correct 
gene transplacement was confirmed by restriction digestion and Southern 
analysis, as before. 
Construction of  an fpr2 Null Mutation 
The FPR2 gene was cloned, based on its published sequence (Nielsen et al., 
1992), by amplification via the polymerase chain reaction (PCR) using S. 
cerevisiae g nomic DNA as the template and a Y-primer, 5'-CGGGATCCA- 
TTATC'I'CACCAGTTACCCG-3' (corresponding to nuclcotides 107 to 
126), and a T-primer, 5'-CGGAAT1CATATATIG-TAGTTAGAGCCC-3' 
(corresponding to nuclcotides 847 to 866), which included BamHI (5'- 
primer) and EcoRI (Yprimer) restriction sites (italicized). Reactions in 50 
#1 contained 50 rig template DNA, 20 pmol each primer, buffer, dNTPs, 
and AmpliTaq TM polymerase (Perkin-Elmer-Cetus Instrs., Norwalk, CT), as 
recommended by the manufacturer, and were subjected to 30 cycles of the 
following program: 95°C for 30 s, 42°C for 30 s, and 72°C for 30 s. A prod- 
uct of the expected size (760 bp) was obtained, purified by electrophoresis 
on a 1% agarose gel, reamplified, and digested with BamHI and EcoRI. The 
resulting fragment was gel-purified and ligated between the BamHI and 
EcoRI sites in pBlueseript ILlKS+, to create plasmid pBSFPR2. Thefpr2- 
I::UK43 insertion mutation was constructed by digesting pBSFPR2 with 
PacI, which cleaves at codon 38 of the FPR2 coding sequence, converting 
the overhangs so generated toblunt ends, and ligating with a 1.3-kb SmaI- 
PvuII fragment containing the URA3 gene that had been excised from plas- 
mid pJJ244 (Jones and Prakash, 1990), to generate plasmid pFPR2D1. 
Plasmids 
The 2.2-kb genomic HindIII fragment containing FPR3 was excised from 
pBYNGI and inserted into HindIII-digested YEp351 (Hill et al., 1986), a 
LEU2-containing 2 #m DNA-based muiticopy vector, yielding YEpFPR3. 
As one approach for immunodetection, the FPR3 coding sequence was 
tagged near its NH2-terminal end by the in-frame insertion of a double- 
stranded synthetic oligonocleotide encoding EEOKLISEEDLD, which con- 
tains an antigenic determinant from the c-Myc oncoprotein (underlined) 
that is recognized by a highly specific monoclunal ntibody, 9El0 (Evan et 
al., 1985). For this purpose, a sense oligonucleotide (5'-CGAAGAACA- 
AAAATTGATTTCCGAAGAAGATTTGGA-3~ was annealed to an anti- 
sense oligonucleotide (5'-CGTCCAAATCTTCTTCGGAAATCAATTTTT- 
GTTCTT-3') and then iigated just after codon 43 (at the ClaI site) in the 
FPR3 coding sequence (see Fig. 1) in plasmid pNH2.2C. The resulting plas- 
raids were screened by DNA sequence analysis for those containing a single 
c-myc epitope in the correct orientation, and one such plasmid was desig- 
nated pUCFPR3myc. The 2.2-kb HindllI fragment containing FPR3myc 
was excised from pUCFPR3myc and inserted into HindIII-digested pRS315, 
a LEO2-containing CEN-based low-copy-number vector (Sikorski and 
Hieter, 1989), to generate pYBI41, and also inserted into YEp351, to pro- 
duce the multi-copy plasmid pYB1010. 
To place FPR3 expression under the control of a regulatable promoter, 
a new LEU2-containing multi-copy vector was constructed asfollows. The 
850-bp EcoRI-BamHI fragment containing the bidirectional GALI-GALIO 
promoter (Johnston and Davis, 1984) was inserted between the EcoRI and 
BamHI sites of YEp351, to create plasmid YEp351GAL. A similar ap- 
proach was used previously to construct a similar, hut URA3-contalning, 
multi-copy vector, YEp352GAL (Benton et al., 1990). To facilitate manip- 
ulation of the FPR3 and FPR3myc coding sequences, a BamHI site was in- 
troduced just upstream (position -18) of the presumptive initiator methio- 
nine codon (where +1 is the first base of the ATG codon) by site-directed 
mutagenesis a  follows. A 900-hp bhnt[Aflm]-EcoRI fragment containing 
the 5'-region of FPR3, and an otherwise identical fragment containing the 
Y-region of FPR3myc, were excised from plasmids pNH2.2 and pUC- 
FPR3myc, respectively, inserted into HincII-EcoRI-digested M13mpl9 RF 
DNA, to create mp197125 and mp1971myc, respectively. Single-stranded 
DNA was prepared using M13KO7 helper phage, according to standard 
procedures (Sambrook et al., 1989). A mutagenic oligonucleotide 
(5'-~TGGTTCK]ATCCTIGCTTTC), which contains a C-to-G transi- 
tion at position -17, was annealed to the single-stranded mp197125 and 
mp1971myc DNA and extended using Klenow fragment and a commercial 
reagent kit (Version 2.1, Amersham Corp., Arlington Heights, IL) for 
oligonucleotide-directed in vitro mntagenesis, under conditions recom- 
mended by the manufacturer. Candidate mutants were screened by digestion 
with BamHI and confirmed by direct nucleotide sequence analysis. The 
900-bp BamHI-EcoRI fragments so generated were inserted into the E. coli 
expression plasmid pGEXZr (Pharmacia LKB Nuclear, Gaitbersburg, MD) 
that had been digested with BamHI and EcoRI, to produce plasmids 
pGXFPR3A and pGXFPR3mA. To reconstruct the full-length reading 
frames of FPR3 and FPR3myc, a 700-bp EcoRI fragment containing the 
COOH-terminal coding segment of FPR3 was excised from plasmid pNB3.3 
and inserted into the EcoRI sites of plasmids pGXFPR3A and pGXFPR3mA, 
and then screened for the correct orientation by restriction mapping. 
Two plasmids that met this criterion were designated pGXFPR3B and 
pGXFPR3mB, rspectively. To place the FPR3 and FPR3myc coding se- 
quences under control of the GAL/promoter, the 1440 BamHI-HindRl frag- 
ments were excised from pGXFPR3B and pGXFPR3mB and ligated with 
YEp351GAL that had been digested with BamHI and HindlII, thereby 
yielding pYB123 (GALI-FPR3) and pYB124 (GALI-FPR3myc). 
Construction of  NHr  and COOH-Terminal 
Truncations of  FPR3 
To truncate the NHz-terminus and express just the COOH-terminal domain 
of FPR3, a BamHI site was introduced and a Lys-to-Met mutation was gen- 
erated at codon 302 of the FPR3 coding sequence (see Fig. 1) in a single 
step by PCR amplification, performed as described above, using plasmid 
pNH2.2 as the template and a 5'-primer, 5'-CCGGATCCCATAATGAGT- 
AAGGTTTTC_K3AAGC~-3' (corresponding to nucleotides 1182-1202), 
and a 3'-primer, 5'-GC~ATGCAAGCTFATAAAGAGC-3' (corresponding 
to ancicotides 1629-1650), which included BamHI (5'-primer) and HindIII 
(3'-primer) estriction sites (italicized). The resulting 470-bp product was 
digested with BamHl and HindIII, purified by electrophoresis in a 1.5% 
agarose gel, and ligated between the BamHI and HindIII sites in pBluescript 
II KS+, yielding plasmid pEB22, whose nucleotide sequence was con- 
firmed by direct DNA sequence analysis. To place expression ofthe COOH- 
terminal domain of FPR3 under GAL/ promoter control, the insert from 
pEB22 was inserted into BamHI and HindIII-digested YEp351GAL, to 
create plasmid pYB120 (GALI-FPR3C). 
To truncate the COOH terminus and express just the NH2-terminal do- 
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main of FPR3, the 1406-bp fragment containing FPR3myc was released by 
digestion of YEp351GALFPR3myc with BamHI and Hindl]I and inserted 
into pUC19-RI, yielding pJHZ4, pJHZ4 was then digested with EcoRI and 
HindlII, which excises afragment that removes all of the sequences beyond 
codon 229. To reattach sequences corresponding to codons 230-301 (which 
includes those residues immediately upstream of, but not including, the 
COOH-terminal catalytic domain) followed by multiple in-frame stop co- 
dons and a HindlII site, PCR was carried out, essentially as described 
above, using YEp351GALFPR3myc as the template and a 5'-primer 
(5 '-GGAGAAGAAGAACAAGAAG-3 '),corresponding to nucleotides 685- 
703, and a 3'-primer (5'-GCGCGAAGCTIV_ACTATTATGGTTTATG- 
CTTATCTTGTTCC-3', corresponding to nacleotides 882-903 and con- 
taining three in-frame termination eodons (underlined), a HindllI site 
(bold-face), and a GC-clamp (italic) to enhance subsequent digestion by 
HindllI. The resulting 243-bp roduct was digested with EcoRI and HindIII 
and ligated into pJHZ4 that had been digested with EcoRI and HindlII and 
treated with shrimp alkaline phosphatase. Individual E. coli transformants 
were subjected to DNA sequence analysis and one such isolate that was 
found to contain o extraneous mutations (other than those purposefully in- 
troduced by the PCR strategy) was designated pJHZ2. To place expression 
of the NH2-terminal domain of FPR3 under GA/_J promoter control, the in- 
sert from pJHZ2 was excised with BamHI and Hindlll and inserted into 
BamHI- and HindllI-digested YEp351GAL, to create plasmid pJHZ3, now 
designated pYB126 (GAL/-FPR3Nmyc). 
Bacterial Expression and Purification of Fpr3 
To express full-length Fpr3 in E. coli, the FPR3 coding sequence was fused 
in-frame to the COOH terminus of Schistosoma j ponicum glutathione 
S-transferase (GST) in the vector, pGEX-2T (Pharmacia, LKB Nuclear), 
as an intermediate step (PGXFPR3B) in producing pYBI23 (GALI-FPR3) 
(see above). The resulting plasmid, pGXFPR3, directs ynthesis of a GST- 
Fpr3 chimera in which the Met at the NH2 terminus of Fpr3 is separated 
from the COOH terminus of GST by a thrombin cleavage site and a four 
amino acid (VQPN) spacer. Cleavage of the fusion protein with thrombin 
releases Fpr3 with a six-residue NH2-terminal extension (H2N-GSVQPN). 
A 2-1 culture ofE. coli strain BL21 carrying plasmid pGXFPR3 was grown 
at 37°C in 2× LB medium (2% Bacto-tryptone, 1% Bacto-yeast extract, 
1% NaCI, 10 mM Tris-Cl pH Z5, 1 mM MgSO4) supplemented with 100 
#g/mi of ampicillin to an At00,m = 0.5. Protein expression was induced by 
addition of IPTG to a final concentration f0.5 mM and the culture was 
incubated for another 2h. Ceils were harvested by centrifugation for 5 rain 
at 4100 g in a Sorvall GSA rotor at 40C, and all subsequent steps were per- 
formed at 4°C unless otherwise stated. The cell pellet was washed once by 
resuspension a d recentrifugation in 100 mM KC1, 0.5 mM PMSF, 50 mM 
K-phosphate (.oH 7.5) and resuspended in three times (wt/vol) the amount 
of the same buffer. Cells were broken by sonic disruption and the lysate was 
clarified by centrifugation for 30 rain at 20,000 g in a Sorvall SS-34 rotor 
This crude extract was mixed batchwise with 1 ml of preswollen glu- 
tathione-Sepharose beads (Pharmacia LKB Nuclear) and incubated for 1 h 
on a rotary mixer. The beads were collected by brief centrifugation, washed 
by resuspension a d recentrifugation in 10 vol of lysis buffer, and poured 
into a column, which was then washed exhaustively with 20 vol of 400 
mM NaCI, 50 mM K-phosphate (pH 7.5). Adsorbed GST-Fpr3 was elnted 
with 5 mM reduced glutathione in 100 mM NaCI, 50 mM K-phosphate 
(pH 7.5) containing 30% glycerol. Fractions (0.2 ml) were collected, 
subjected to SDS-PAGE, and visualized by both Coomassie blue staining 
and immunoblotting (see below). Peak fractions were pooled and concen- 
trated to 9 mg/ml by centrifugation i  a Centricon-30 chamber (Amicon, 
Bevedy, MA). To release Fpr3 from the fusion, reactions containing 
1 mg/ml GST-Fpr3 and 10/~g/ml thrombin (Sigma Chem. Co., St. Louis, 
MO) in TBS (140 mM NaC1, 20 mM Tris-Cl, pH 7.5) supplemented with 
2 mM CaCI2 were performed at 25°C for 30 min. After digestion, the mix- 
ture was chilled on ice and the GST fragment was removed by adsorption 
to glutathione-Sepharose beads, essentially as described above. The beads 
were removed by centrifugation a d the supernatant fraction was stored at 
4°C before analysis. Protein concentration was determined by a dye-binding 
method (Bradford, 1976) using a commercial reagent kit (Bio Rad Labs, 
Hercules, CA). 
To express the COOH-terminal domain of Fpr3 (=Fpr3C') in E. coli, the 
COOH-terminal 134 codons of FPR3 were fused in-frame to the NH2- 
terminal 13 amino acids of T4 lysozyme by inserting a 530-bp blunt- 
[EcoRt]-HindlII fragment of FPR3 between the Sinai and HindlIl sites in 
the vector, pEXP1 (Raymond et al., 1990), to create plasmid pT4FPR3C. 
Protein expression i E. coli strain BL21 and preparation of the crude ex- 
tract were as described above, except he lysis buffer was 5 mM 2-mer- 
captoethanol, 0.5 mM PMSF, 20 mM Tris-Ci (pH 8.0). The crude ex- 
tract was adjusted to a final concentration f2% protarnine sulfate and the 
resulting nucleic acid precipitate was removed by centrifugation. The result- 
ing supernatant fraction was then adjusted with (N1~)2SO4 to 40% of satu- 
ration, which resulted in nearly quantitative precipitation of Fpr3C. This 
pellet of precipitated protein was redissolved inlysis buffer containing 5 % 
glycerol, dialyzed overnight against the same buffer, and subjected to chro- 
matography on a Mono-Q column (Pharmacia LKB Nuclear) using an auto- 
mated FPLC apparatus (Waters Instrs. Inc., Rochester, MN). Fpr3C was 
found in the flow-through fraction, whereas most of the contaminating pro- 
teins were adsorbed. The flow-through fraction was dialyzed against 50 mM 
NaCI, 5% glycerol, 0.5 mM PMSF, 20raM Hepes (pH 7.8), and subjected 
to FPLC on a Mono-S column (Pharmacia LKB Nuclear), which was eluted 
with a linear gradient from 50 to 600 mM NaCI in the same buffer. Peak 
fractions were pooled, dialyzed against the same buffer, adjusted to a final 
concentration f50% glycerol, and stored at -20°C before analysis. 
To express the NH2-terminal domain of Fpr3 ("Fpr3N ~) in E. coli, the 
NH2-terminal 279 codons of Fpr3 were fused in-frame to the COOH ter- 
minus of GST in the vector, pGEX-2T (Pharmacia LKB Nuclear), as an in- 
termediate step (pGXFPR3A) in producing pYB123 (GALI-FPR3) (see 
above). Expression and purification of the GST-Fpr3N fusion protein from 
E. coli strain BL21 carrying pGXFPR3A was performed exactly as de- 
scribed above for full-length Fpr3. 
Assay of Peptidylprolyl-cis, trans-lsomerase Activity 
Proline rotamase activity was measured as the rate of enhancement of the 
cleavage of a Pro-containing chromogenic peptide substrate by chymotryp- 
sin using a spectrophotometer (Fischer et al., 1989). Peptides containing 
Pro exist as an equilibrium mixture of the cis and trans isomers about he 
X-Pro bond. Chymotrypsin will only cleave on the C-side of an X-Pro bond 
when it is in the trans configuration. Therefore, conversion of the cis to 
trans isomer catalyzed by a PPIase enhances the rate of substrate hydrolysis 
by chymotrypsin. Measurement ofthe activity of two different preparations 
of Fpr3C was kindly performed by Felicia Etzkorn in the laboratory of 
Christopher Walsh (Department of Biological Chemistry and Molecular 
Pharmacology, Harvard Medical School, Boston, MA). Reaction mixtures 
(1 ml), assembled on ice, contained 70 #M of either N-succinyl-Ala-Ala- 
Pro-Phe-p-nitroanilide or N-succinyl-Ala-Leu-Pro-Phe-p-nitroanilide, 100 
mM Tris-Cl (pH 7.5), and varying amounts of purified Fpr3 or Fpr3C 
(0.2-1.2 #M). Reaction mixtures were equilibrated to 10°C and initiated by 
addition of c~-chymotrypsin (100/~g/ml). The change in absorbance at400 
mn (or 390 rim) was monitored at 0.1-1.0-s intervals over the course of about 
2 min using a Hewlett-Packard 8452A (or a Shimadzu UV160A) spec- 
trophotometer. When the effects of FK506 and rapamyein were tested, Fpr3 
was incubated on ice with a 10-fold molar excess of the drug (prepared as 
a stock in methanol) for 10 rain before assembling reaction mixtures. An 
equal volume of methanol a one had no detectable effect on the PPIase activ- 
ity of Fpr3. 
Preparation of Anti-Fpr3 Antibodies 
Antisera to recombinant Fpr3 were raised in adult female New Zealand 
white rabbits using standard procedures (Harlow and Lane, 1988) as fol- 
lows. Serum no. 1138 was raised against purified Fpr3C (Mono-Q fraction). 
Serum no. 1139 was raised against the purified GST-Fpr3N fusion protein. 
The anti-Fpr3 immunoglobulins from both antiserum no. 1138 and antise- 
rum no. 1139 were enriched by affinity purification of these antisera on 
columns consisting of GST-Fpr3 that had been immobilized on CNBr- 
activated Sepharose beads (Pharmacia LKB Nuclear). After washing these 
columns extensively with 1 M NaCI, the specific antibodies wore eluted 
with 50 mM glycine (pH 2.4) and the resulting eluate was immediately neu- 
tralized by the addition of one-tenth volume of 0.5 M Na2HPO4. Anti-yeast 
fibrillarin antibodies (mAb A66) were the gift of Dr. John Aris (Dept. of 
Anatomy and Cell Biology, University of Florida, Gainesville, FL). 
Gel Electrophoresis and Immunoblotting 
Yeast cells were grown to mid-exponential phase (A~om = 0.75-1) in rich 
medium (YPD), harvested by brief centrifugation, washed once in water, 
and resuspended in 0.3 ml ice-cold lysis buffer (150 mM NaCI, 50 mM 
Tris-Cl, pH 8.0, 1 mM PMSF, 1 mM EDTA, 1% Triton X-100, 0.5% SDS) 
at 40-50 At,0o~ units per ml. The cells in the suspension wore lysed by six 
30-s periods of vigorous vortex mixing (separated by l-rain periods of cool- 
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ing on ice) with 0.3 g of prechilled glass beads (0.45-0.6 mm diameter). 
The lysates were adjusted to 2% SDS, boiled for 3 min, cooled to room 
temperature, and clarified by ceatrifitgation at 10,000 g for 10 min to re- 
move the beads and cell debris. Protein in the clarified extracts was precipi- 
tated with trichloroacetic acid (10% final concentration), resolubilized in 
SDS-PAGE and sample buffer, and subjected to SDS-PAGE (Laemmli, 
1970). Proteins were visualized by staining with Coomassie blue (Weber 
and Osborn, 1969) or silver (Oaldey et ai., 1980). 
Transfer of proteins resolved by SDS-PAGE to nitrocellulose (BA85, 0.45 
nun: Schleicher & Schueii) was performed using procedures described in 
detail elsewhere (Towbin et ai., 1979). Blots were blocked and incubated 
with the primary antibodies using standard procedures (Hariow and Lane, 
1988) and immune complexes were detected using secondary anti-IgG anti- 
bodies coupled to horseradish peroxidnse and a chemiluminescence detec- 
tion system (FJ2L TM, Amersbam Corp.), according to the manufacturer's in- 
structions. E coil cell extracts and purified fractions containing Fpr3 or any 
of its derivatives were solubilized and analyzed by SDS-PAGE and immuno- 
blotting using procedures essentially identical to those used for yeast ex- 
tracts. 
lmmunofluorescence 
Staining of yeast cells by indirect immunofluorescence was performed es- 
sentially as described by Rose and Fink (1987), with the following 
modifications. Cell walls were removed by incubation with 20 #g/ml 
Zymolyase-100T (Seikngaku America Inc., Rockville, MD) at 30°C for 
30-45 rain. The primary antibodies (either afffinity-purified IgGs from an- 
tisera no. SB126, no. 1138, and no. 1139, all diluted to 1/~g/ml, or ascites 
fluid containing anti-c-Myc mAb 9El0, diluted 1:200) were incubated with 
the fixed cells at room temperature for 1-2 h. Secondary antibodies (1:200 
diluted, affinity-purified, FITC-, Texas Red- or rhodamine-labeled, goat 
anti-rabbit IgG antibodies or goat anti-mouse IgG antibodies; Jackson Im- 
munoResearch Labs., Inc., West Grove, PA) were applied for 1 h. Cells 
were examined with a Nikon Optiphot epiflunrescence microscope using a 
100x objective and photographed with Kodak Ektachrome Elite 400 color 
slide film. 
Measurement ofSensitivity of Rapamycin Action 
A bioassay was used to determine the relative sensitivity of cells to the 
growth inhibition caused by rapamycin. Samples (200/~1) of cell suspew 
sions (exponential cultures at ,x,l x 107 cells per nil) of the strains to be 
tested were used to inoculate 3 rnl of molten soft (0.7%) agar containing 
SD medium and were immediately poured uniformly over the surface of an 
SD plate containing nutrients appropriate for the maintenance of plasmids, 
if present. After solidification of the top agar, sterile cellulose filter disks 
(0.6 cm diameter; Difco Laboratories, Detroit, MI), each containing a 
different known concentration f rapamycin that was spotted in an identical 
volume of ethanol containing 10% Tween-20, were placed aseptically on 
the surface of the agar. The plates were incubated at 30°C for ,~48 h until 
the lawns were clearly visible. As in other agar diffusion assays of drug sen- 
sitivity, the radius of the halo of growth inhibition in the lawn surrounding 
the disk is proportional to the logarithm of the initial concentration f the 
drug applied to the disk (Cooper, 1963). Alternatively, various amounts of 
the drugs were added irectly to vigorously stirred molten (60°C) agar from 
a concentrated stock in ethanol containing 10% Tween-20 just before pour- 
ing into Petri plates. Rapamycin was the generous gift of Suren Sehgal 
(Wyeth-Ayerst Research Laboratories, Princeton, NJ). FK506 was the 
generous gift of Ihor Bekersky (Fujisawa USA, Inc., Melrose Park, IL). 
Results 
Isolation and Characterization fthe FPR3 Gene 
As one means toward identifying previously unknown pro- 
teins that may be involved in events that regulate the architec- 
ture and metabolism of the yeast cell nucleus, we raised 
polyclonal antisera directed against several polypeptides that 
were abundantly represented in preparations ofS. cerevisiae 
nuclei which we believed to be highly enriched in the nuclear 
envelope fraction. The methods we used for subcellular f ac- 
tionation have been reported to yield a subnuclear f action 
that is supposed to be devoid of chromatin and its associated 
proteins (Aris and Blobel, 1988, 1989, 1991). Prominent 
polypeptides in these preparations, as detected by SDS- 
PAGE and Coomassie blue staining, were excised from 
preparative gels and injected into rabbits. The same protein 
species immobilized by transfer to nitrocellulose filters were 
used to immuno-select specific antibodies from the poly- 
clonal sera. The afffinity-purified antibodies then were used 
to stain fixed and permeabilized yeast cells by indirect im- 
munofluorescence. Antibodies obtained from an antiserum 
that was raised against a relatively abundant nuclear protein 
with an Mr~ of 65 kD decorated a polypeptide of identical 
mobility on immunoblots of fractionated nuclear extracts 
and displayed exclusively nuclear staining when examined by 
indirect immunofluorescence. 
The affinity-purified antibodies directed against the 65-kD 
species were used to screen a yeast genomic DNA library 
in the kgtll expression vector. The insert from the single im- 
munoreactive phage so obtained was subeloned, and DNA 
sequence analysis revealed a open reading frame of 1239 bp 
(Fig. 1 A). Using the phage insert as a probe, a genomic frac- 
tion covering this same region was recovered from an inde- 
pendent yeast genomic DNA library in a plasmid vector. 
DNA sequence analysis of the insert in the plasmid con- 
firmed the sequence of the open reading frame and extended 
the sequence in the regions immediately flanking the open 
reading frame (Fig. 1 A). The open reading frame predicts 
a protein of 413 amino acids, with a calculated molecular 
weight of 46,800. The NH2-terminal two-thirds of the 
predicted primary sequence contains an unusually large 
number of charged residues (Fig. 1 A), arranged as long 
tracts of acidic residues eparated by shorter stretches of ba- 
sic residues, which is known to cause an anomalously slow 
mobility upon SDS-PAGE (for example see Fuller et al., 
1989) and presumably accounts for its higher apparent mo- 
lecular mass (~65 kD) when determined by this method. 
The sequence contains at least one match to the consensus 
bipartite nuclear localization signal, -KK-(X)I0-KAK~ 
KVKK- (residues 258-276) (Robbins et al., 1991). Compari- 
son of the open reading frame to all available protein se- 
quences in the GenBank database using the BLASTP 
algorithm (Altschul et al., 1990) revealed that the COOH- 
terminal 111 residues of the open reading frame (Fig. 1 A, 
underlined) share over 40% identity with various members 
of the FKBP family from yeast, Neurospora cmssa, and hu- 
mans (Fig. 2). Hence, we designated the gene encoding this 
protein FPR3 (for FKSO6-binding proline rotamase number 
3) because it was the third yeast FKBP identified (Kunz and 
Hall, 1993). The FPR3 gene product, Fpr3, was also termed 
yFKBP-47, in keeping with a suggested nomenclature for 
FKBPs (Jin et al., 1991). 
To determine if FPR3 is an expressed gene, DNA probes 
internal to the coding region were hybridized to preparations 
of poly(A) + RNA isolated from MA~a and MATtx haploids 
and MATa/MAT~ diploids. A transcript of about 1,400 
nucleotides, which is of sufficient length to contain the entire 
predicted open reading frame, was readily detectable in all 
three cell types (data not shown). The location of the FPR3 
gene on the physical and genetic maps of the S. cerevisiae 
genome was then determined (see Materials and Methods). 
DNA probes internal to the coding region hybridized to the 
band representing chromosome XIII on blots of intact chro- 
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A 
- 279 CACTAAATCTGGTT~ATCTACATCTATATAGTCAAAACAGGC~G~CAGAGTTATGATACAT~TTCATGTTCCAT 
- 201 TGTTAG~TCCACTAGTATTAGCTCGCTGTTC~TTTTCA~CCTCTACGGACTGTCGTCATTCCTAAAGGACGGC~ 
- 123 ~TTTAAAAGTG~GGTAAAATTTTTAAATTCGAAAAAAGA~CTACT~CACGTTTCTATAT~TACAT~TTGTGT 
45 GAAAGTTCATACAT~TTGAAAGC~GCATCC~CCA~CC~T 
+ 1 ATGTCTGATTTGTTACCACTAGCTACCTACAGTTTG~TGTTG~CCTTATACCCCGGTTCCAGC~TCGACGTCACG 
M S D L L P L A T Y S L N V E P Y T P V P A I D V T  26 
+ 79 ATGCCCATCACCGTTCGTATTACTATGGCTGCTTTG~CCCGG~GCCATCGATG~GAG~CAAACCATCGACTTTA 
M P I T V R I T M A A L N P E A I D E E N K P S T L  52 
+ 157 AG~TTATCAAAAGAAACCC~ACTTTG~GATGATGATTTTTTAGGT~TGATTTTGATG~GACGAAATAGACG~ 
R I I K R N P D F E D D D F L G G D F D E D E I D E  78 
+235 G~TCCTCTGAGG~G~G~GAGGAAAAAACCCAAAAGAAAAAG~GAGTAAA~C~G~CTGAAAGTGAAAGT 
E S S E E E E E E K T Q K K K K S K G K K A E S E S I 0 4  
+ 313 GAGGATGATG~G~GACGATGACGAGGACGATGAGTTCC~G~TCCGTCCCTTTGACTTTATCTCCGG~CC~ 
E D D E E D D D E D D E F Q E S V L L T L S P E A Q I 3 0  
+ 391 TACC~C~TCTTT~ACTTGACCATTACTCCAG~G~G~GTCC~TTC~TGTCACT~TTCTTACGCTATCTCC 
Y Q Q S L D L T I T P E E E V Q F I V T G S Y A I S I 5 6  
+ 469 TTGAGCGGT~CTATGTT~GCATCCATTTGATACTCC~TGGGAGTCG~GGTG~GACG~GATG~GACGCTGAC 
L S G N Y V K H P F D T P M G V E G E D E D E D A D I 8 2  
÷ 547 ATCTATGACAGTG~GACTACGACTTGACCCCAGATGAGGATGAAATTATTGGCGACGACATGGACGACTTGGATGAC 
I Y D S E D Y D L T P D E D E I I G D D M D D L D D 2 0 8  
+625 G~GAGG~G~G~GTTCGTATTG~G~GTCC~G~G~GATG~G~GAT~TGATGGAG~G~G~C~G~ 
E E E E E V R I E E V Q E E D E E D N D G E E E Q E 2 3 4  
+703 G~G~G~G~G~G~G~G~CAAAAAG~G~GTT~GCCAG~CCT~GAAAAGCAAAAAGGAAAAAAAGAGA 
E E E E E E E E Q K E E V K P E P K K S K K E K K R 2 6 0  
+781 ~GCACG~GAGAAAG~G~GAAAAGAAAGCTAAAAAAGTAAAG~GGTCG~TTC~G~ACTTAGAGGAGGGT 
K H E E K E E E K K A K K V K K V E F K K D L E E G 2 8 6  
+859 CC~CAAAACCCAAAAGCAAAAAGG~C~GAT~GCATAAACCAAAGAGT~GGTTTTGG~G~CATAGT~TC 
p T K P K S K K E Q D K H K P K S K V L E G G I V I 3 1 2  
+ 937 G~GACCGTACTATCGGTGATG~CCACAGGCT~GAGAGGT~CAGAGTAOGCATGAGGTACATTGGT~GTTC~G 
E D R T I G D G F O A ~ G A R V G M R Y I G K L K _ 3 3 8  
+1015 ~CGGTAAAGTTTTCGAC~G~CACCA~GGTAAACCATTTGCATTCAAACTTGGCCGTGGTG~GTTA~AAAGGC 
N G K V F D K N T S G K P F A F K L G R G E V I K G 3 6 4  
+1093 TGGGACATTGGTGTTGCCGGTATGTCTGTT~TGGCG~CGTAG~TCATCATTCCAGCACCATATGCCTACGGG~G 
W D I G V A G M Z V G G E R R I I I P A P Y A Y G K . , 3 9 0  
+1171 C~GCTCTGCCAGGTATTCCTGCC~TTCCG~CTGACATTCGACGTTAAATTGGTTTCTATGAAAAACTAGTACACG 
Q A L P G I P A N g E L T F D V K L V S M K N  413 
+1249 CGCTCGTACGGATAGATGTTTATATATATTATTCTTTTTACAT~TATTGT~CCTTCTGTATGTAAATCCGAAAACA 
+1327 TTCTATTTCTTTTTAGTATCTATTGCTCTTTAT~GCTTGCATGCCTGCAGGTCGACTCTAGAGGATCCTCG~TACC 
+1405 GAGCTCG~TT~TTCACTGGCCGTCGTT 
s 
[ I i 
100 bp 
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Figure 1. Sequence of the 
FPR3 gene and structure of 
fpr3 null mutations. (,4) Nu- 
cleotide sequence and de- 
duced amino acid sequence of 
the FPR3 gene. Numbers to 
the left represent bases in the 
nucleotide sequence (where 
+1 is the A of the presumptive 
ATG initiator codon). Num- 
bers to the right represent 
amino acids in the predicted 
primary sequence (given in 
the single letter code). Arrow- 
head indicates the position 
(between codons 43 and 44) 
where a c-myc epitope tag 
was inserted to create the 
FRP3myc allele (see Ma- 
terials and Methods). The 
COOH-terminal region ho- 
mologous to FKBPs is under- 
lined (see also Fig. 2). The 
GenBank accession number 
for this sequence is L34569. 
(B) Restriction endonuclease 
cleavage site map of the 2.2- 
kb genomic HindlII fragment 
that contains the FRP3 locus. 
In the fpr3-Ah:URA3 allele, 
codons 44-279 were deleted 
and replaced by the URA3 
gene. In the fpr3-2::HIS3 al- 
lele, the coding sequence was 
disrupted by insertion of the 
HIS3 gene immediately after 
codon 386. 
mosomes separated by clamped homogeneous field elec- 
trophoresis (data not shown) and hybridized specifically to 
a lambda phage carrying a particular subfragrnent of the far 
left arm of chromosome X~I, just centromere-distal to the 
HMG1 gene (data not shown). To confirm this conclusion, 
a genetic cross was performed between a MA/h strain 
(YB100) carrying a URA3 marker inserted into the FPR3 
gene and a MATs strain (YB58) carrying a LYS2 marker in- 
serted into the HMGI gene. Tetrad analysis (PD:NPD:T:: 
29:0:0) demonstrated that the FPR3 locus is indeed very 
tightly linked to the HMG1 locus. 
FPR3 Gene Product Has Peptidylprolyl-cis, 
trans-lsomerase Activity In Vitro 
Although the COOH-terminal portion of Fpr3 shares a high 
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Figure 2. Homology of the COOH-terminus of Fpr3 to known 
members of the FKBP family. The COOH-terminal 111 amino 
acids (residues 302-413) of Fpr3 (yFKBP-47) are compared with 
the predicted primary sequences of yeast FKBP-12 (yFKBP-12) 
(Heitman et al., 1991b; Koltin et al., 1991; Wiederrecht et al., 
1991), human FKBP-12 (hFKBP-12) (Standaert et al., 1990), yeast 
FKBP-13 (yFKBP-13) (Nielsen t al., 1992), human FKBP-13 
(hFKBP-13) (Jin et al., 1991), and Neurospora crassa FKBP-14 
(NcFKBP-14) (Tropschug et al., 1990). White-on-black letters in- 
dicate amino acid identities. Dashes indicate single-residue gaps in- 
troduced to maximize the alignment. 
degree of amino acid sequence identity with known FKBPs 
and each of the residues known to line the substrate-binding 
pocket in human FKBP-12 (Tyr27, Phe37, Trp60, Tyr 83 and 
Phel00; Fig. 2) (Becker et al., 1993; Rotonda et al., 1993) 
are completely conserved in Fpr3, it was nonetheless impor- 
tant to demonstrate hat, like other FKBPs, Fpr3 is indeed 
a functional PPIase. For this purpose, a construct was made 
(see Materials and Methods) that permitted expression of the 
COOH-terminal 134 residues, which includes the presump- 
tive catalytic domain, in E. coli. This soluble protein, 
Fpr3C, was purified to apparent homogeneity (Fig. 3 A). In 
addition, full-length Fpr3p was expressed in E. coli as a fu- 
sion protein to S. japonicum glutathione S-transferase, 
yielding a GST-Fpr3 chimera of Mr~ ~95kD. The soluble 
GST-Fpr3 fusion protein was purified to near homogeneity 
by adsorption and elution from glutathione-Sepharose beads 
(Fig. 3 B). Fpr3 (with a short 6-amino acid NH2-terminal 
extension) was released by digestion of the GST-Fpr3 fusion 
with thrombin, and the bulk of the free GST and uncleaved 
GST-Fpr3 were removed by their readsorption to glutathi- 
one-Sepharose (Fig. 3 B). The isolated catalytic domain, 
Fpr3C, possessed readily detectable PPIase activity, as mea- 
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Figure 3. Purification and in 
vitro PPIase activity of bac- 
terially expressed Fpr3. (,4) 
Purification of the Fpr3C do- 
main. E. coli (2 x 10 ml cells) 
carrying plasmid pT4FPR3C 
were grown, induced, har- 
vested and lysed, and Fpr3C 
was purified from the result- 
ing extracts, as described in 
detail in Materials and 
Methods. Samples ('~10 #g 
total protein each) from vari- 
ous stages of the purification 
were resolved by SDS-PAGE 
in a 15% gel and stained with 
Coomassie blue dye. Clarified 
lysates of uninduced (-)  and 
IPTG-induced (+) cultures; 
material precipitated from the 
extract of IPTG-induced cells 
by addition of (NI-h)2SO4 to 
40% of saturation (AmSO~); 
flow-through fraction follow- 
ing chromatography of the 
redissolved (NI-h)2SO4 pre- 
cipitate on Mono-Q (MonoQ); 
pooled peak fractions of the 
eluate following chromatog- 
raphy of the Mono-Q pass-through on Mono-S (MonoS). Arrowhead indicates purified Fpr3C. (B) Purification of full-length Fpr3. E
coli carrying pGEXFPR3 were grown, induced, harvested and lysed, and the GST-Fpr3 fusion protein was purified and cleaved, as de- 
scribed in detail in Materials and Methods. Samples (~5 #g total protein each) from various stages of the purification were resolved by 
SDS-PAGE in an 8% gel and stained with Coomassie blue dye. Clarified lysates of uninduced (-)  and IPTG-induced (+) cultures; 
glutathione eluate of the material bound pon incubation of the extract of IPTG-induced cells with glutathione-agarose before treatment 
with thrombin (-73; material that no longer adsorbed to glutathione-agarose after treatment with thrombin (+73. Arrowhead indicates 
purified Fpr3. Molecular masses (×10-3) of markers were: 14 kD, egg white lysozyme; 22 kD, soybean trypsin inhibitor; 31 kD, ca bonic 
anhydrase; 43/45 kD, ovalbumin; 68 kD, bovine serum albumin; 97 kD, phosphorylase b; 116 kD, E. coli/~-galactosidase; and200 kD, 
myosin heavy chain. (C) PPIase activity of the Mono-Q (open symbols) and Mono-S (closed symbols) fractions of the preparation f Fpr3C 
shown in A were assayed using 70 #M N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide as the substrate in a coupled assay with chymotrypsin, 
as described in Materials and Methods. T e initial rate of hydrolysis (kobs) was measured in the absence and in the presence of the indi- 
cated concentrations f Fpr3C. 
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sured by enhancement of the rate of chymotrypsin cleavage 
of a synthetic Pro-containing peptide substrate in a coupled 
spectrophotometric assay (Fig. 3 C). The specific activity of 
full-length Fpr3 was not significantly different from that of 
its isolated COOH-terminal domain (data not shown). Simi- 
lar to other FKBPs from humans (Park et al., 1992) and 
yeast (Nielsen et al., 1992), both full-length Fpr3 and Fpr3C 
reproducibly displayed a significantly faster ate (/>twofold) 
• of isomerization fa peptide substrate containing a Leu-Pro 
bond compared to an otherwise identical substrate contain- 
ing an Ala-Pro bond (data not shown). Also, as predicted 
from its homology to other FKBPs, Fpr3 appeared to be both 
an FK506- and rapamycin-binding protein in vitro because 
addition of a 10-fold molar excess of either compound to 
reaction mixtures completely inhibited its PPIase activity 
(data not shown). This conclusion was further supported by 
in vivo studies (see below). 
Genetic Analysis of FPR3 Function 
Two different fpr3 null mutations were constructed (Fig. 1 
B). The fpr3-AI::URA3 allele is a deletion (codons 44 to 
278), which eliminates a large portion of the open reading 
frame. Thefpr3-2::HlS3 allele contains a large insertion at 
codon 386, which disrupts the catalytic domain. Appropriate 
DNA fragments containing these mutations were used to 
transplace the FPR3 locus on one homologue of chromo- 
some XIII in MATa/MATot diploid recipients. Viable haploid 
spores containing either of the two null alleles were readily 
obtained upon sporulation and dissection of the correspond- 
ing heterozygous fpr3/FPR3 diploid transformants (see, for 
example, Fig. 7 A). It has been observed previously thatfprl 
(Heitman et al., 1991b) andfpr2 (Nielsen et al. 1992) null 
mutants generated in an identical fashion are also viable. 
Therefore, like the FPRI and FPR2 genes, the FPR3 gene 
is dispensible for spore germination and vegetative cell 
growth. 
Haploid fpr3-Al and fpr3-2 strains were examined syste- 
matically for potential phenotypes that might reveal the phys- 
iological function of Fpr3. Compared to otherwise isogenic 
controls, growth offpr3 mutants was unaffected on rich or 
synthetic defined medium containing lucose, glycerol or 
acetate. Thefpr3 mutants were no more cold- (14°C) or heat- 
(36°C) sensitive, or susceptible to heat shock, than the pa- 
rental cells; also, fpr3 mutants were mating proficient and 
displayed no defect in response to (or recovery from) mating 
pheromone-induced llcycle arrest. Homozygousfpr3/fpr3 
diploids sporulated and germinated ata frequency indistin- 
guishable from normal diploids. Similarly, normal FPR3 ÷ 
cells also expressing FPR3 from a 2-#m DNA plasmid, 
which resulted in an •10-fold overproduction f Fpr3, as 
judged by immunoblotting (data not shown), showed" no 
difference from control cells with respect o growth, tem- 
perature-sensitivity, mating ability, or sporulation. Finally, 
bothfpr3 mutants and normal cells carrying FPR3 on a 2-#m 
DNA plasmid isplayed no morphological berrations when 
examined microscopically either by phase contrast or by in- 
direct immunofluorescence when stained with the DNA- 
specific dye, DAPI, or with anti-actin or anti-tubulin anti- 
bodies (data not shown). 
One possible explanation for the lack of a discernible 
phenotype offpr3 mutations was the presence of genes in the 
yeast genome whose products might substitute for FPR3 
function. Low stringency hybridiTation of FPR3 DNA probes 
to total cellular DNA digested with various restriction en- 
zymes did not reveal any evidence for a highly homologous 
gene in the S. cerevisiae genome. However, as mentioned 
earlier, two other FKBP-encoding enes, FPRI (Heitman et 
al., 1991a; Koltin et al., 1991; Wiederrecht e al., 1991) and 
FPR2 (Nielsen et al., 1992), were previously identified in S. 
cerevisiae. Therefore, we tested whether either FPRI or 
FPR2 might be partially redundant in function with FPR3 by 
determining if any phenotypes were revealed by combining 
anfpr3 mutation with mutations in the other two genes. For 
this purpose, aset of otherwise isogenic strains carryingfpr/ 
and fpr2 null mutations, either individually or in combina- 
tion, were constructed and crossed tofpr3 mutants. Sporula- 
tion and dissection of the resulting diploids readily yielded 
fprl fpr3 and fpr2 fpr3 double mutants and even fprl fpr2 
fpr3 triple mutants at the expected frequencies. Further- 
more, like J~or3 single mutants, trains carrying any of these 
combinations of mutations, including thefprl fpr2fpr3 triple 
mutant, had no detectable phenotypes with respect to 
growth, temperature-sensitivity and mating ability. 
Fpr3 Can Bind Rapamycin and FKS06 In Vivo 
Standard laboratory strains of S. cerevisiae, including YPH- 
499 and the derivatives we used in this work, are quite sensi- 
tive to growth inhibition by rapamycin, but are essentially 
unaffected by FKS06. Rapamycin-Fprl complexes appear to 
be targeted to the PI lipid kinases, Torl and Tot2, which are 
enzymes essential for viability (Kunz et al., 1993; Helliwell 
et al., 1994), whereas FKS06-Fprl complexes are targeted 
to calcineurin (Foor et al., 1992), an enzyme that is not es- 
sential for cell growth (Cyert et al., 1991; Cyert and Thorner, 
1992) (although FKS06 at high concentrations can inhibit he 
growth of certain amino acid auxotrophs because itcan block 
the transporters for those amino acids [Heitman et al., 
1993]). Several groups have demonstrated that cells bearing 
anfpr/null mutation are completely resistant to the growth- 
inhibitory action of rapamycin (Heitman et al., 1991ab; Kol- 
tin et al., 1991). Moreover, because FKS06 and rapamycin 
compete for binding to Fprl, FKS06 at moderate concentra- 
tions can actually antagonize the toxicity of rapamycin (Heit- 
man et al., 1991a). 
To determine whether the FPR3 product was capable of 
binding either of these drugs and contributing to their 
growth-inhibitory effect, we first compared the sensitivity of 
isogenic FPR3 cells andfpr3 mutants, in both FPRI andJ~r/ 
backgrounds, todifferent concentrations of rapamycin (data 
not shown). The FPRI fpr3 cells were just as sensitive to 
rapamycin as FPRI FPR3 cells. Furthermore, fprlfpr3 dou- 
ble mutants were no more resistant to rapamycin than fprl 
FPR3 cells. Moreover, the resistance offprl cells and the 
sensitivity of FPR1 cells to rapamycin was unaffected when 
these strains expressed FPR3 from a 2-#m DNA plasmid. 
Because Fprl is a cytosolic protein (also referred to as 
yFKBP-12) and because Fpr3 was initially identified as a nu- 
clear protein, it seems possible that neither drug can affect 
Fpr3 function because thes ecompounds cannot enter the nu- 
cleus or because the downstream targets for the growth: 
inhibitory action of immunophilin-drug complexes are not 
present in the nucleus. To address this issue, we constructed 
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a vector to express just the catalytic domain of Fpr3 because 
we reasoned that the NH2-terminal domain of Fpr3 might 
be responsible for sequestering Fpr3 in the nucleus and/or 
for targeting Fpr3 to a specific substrate(s) in the nuclear 
compartment. For this purpose, we placed the coding se- 
quence for the COOH-terminal 112 residues (where the 
Lys301 codon had been changed to a Met codon) under con- 
trol of the GAL/promoter in a multi-copy vector. As acon- 
trol, we inserted the entire FPR3 gene into the same expres- 
sion vector. 
These plasmids were introduced by transformation into 
otherwise isogenlc FPRI (rapamycin-sensitive) and fprl 
(rapamycin-resistant) strains. First, cells carrying each of 
the two different plasmids were grown on glucose medium 
to mid-exponential phase, and then shifted to medium con- 
tainlng galactose for several hours to induce expression of 
the corresponding genes. As demonstrated by immunoblot- 
ting of cell lysates fractionated by differential centrifugation 
or by indirect immunofluorescence with specific anti-Fpr3C 
antibodies, the Fpr3C domain was expressed as an abundant 
cytosolic protein (data not shown), whereas full-length Fpr3 
was associated exclusively with the nucleus ( ee below). Ex- 
pression of neither plasmid detectably affected (either en- 
hanced or reduced) the rapamycin sensitivity of the FPRI 
cells (data not shown). As expected, however, in fprl cells, 
which are otherwise resistant to rapamycin, expression of 
Fpr3C in the cytosol (but not full-length Fpr3) restored sen- 
sitivity to rapamycin (Fig. 4), although at the level about 10- 
fold lower than that typically displayed by FPRI ceils (data 
not shown). The ability of the Fpr3C domain to functionally 
substitute for Fprl in vivo to mediate rapamycin growth inhi- 
bition indicates that he COOH-terminal catalytic domain of 
Fpr3 is capable of binding rapamycin, confirming the results 
of the in vitro assays performed on the purified protein. Fur- 
thermore, we found that the presence of a large excess of 
FK506 (which by itself is not an efficacious growth inhibitor, 
as mentioned above) was able to partially antagonize the 
Figure 4. The COOH-terminal domain of Fpr3 can function as a 
receptor for raparnycin i  vivo. Strain YBll2 (MATafprl-2::ADE2 
fpr3-2::HIS3) carrying either vector al ne, YEp351GAL (GAL/- 
Vector), or the same plasmid expressing either full-length Fpr3, 
pYB123 (GALI-FPR3), or just he COOH-terminal domain of Fpr3, 
pYB120 (GALI-FPR3C), were plated on SD-Leu medium contain- 
ing either glucose (Glc) or galactose (Gal) and their sensitivity to 
growth inhibition by rapamycin (10/~g total per disk applied in etha- 
nol containing 10% Tween-20) was tested by the halo bioassay de- 
scribed in Materials and Methods. 
toxic effect of rapamycin i  the fpr/cells expressing Fpr3C 
(data not shown), presumably by preventing formation of the 
Fpr3C-rapamycin complex. This observation also supports 
the conclusion that the COOH-terminal domain of Fpr3 is 
capable of binding FK506, in agreement with the results of 
the in vitro assays. 
Overproduction fFpr3 or its NHrterminal Domain is 
Deleterious to Growth 
Although overproduction f full-length Fpr3 from the GAL/ 
promoter did not confer apamycin sensitivity to fprl cells, 
unlike the overproduced Fpr3C domain, we noticed that na- 
scent lawns of cells harboring the GALI-FPR3 plasmid grew 
very slowly when plated on galactose-containing medium, 
but not when plated on glucose-containing medium (Fig. 4). 
Immunoblotting indicated that the level of Fpr3 achieved in 
cells expressing GALI-FPR3 from the multi-copy plasmid af- 
ter several hours of growth on galactose medium was at least 
5-10-fold higher than the level observed when FPR3 was ex- 
pressed from its own promoter on a multi-copy plasmid (data 
not shown). To confirm that his level of Fpr3 overproduction 
was deleterious togrowth, we compared the ability of other- 
wise wild-type cells carrying plasmids expressing either 
GALI-FPR3, GALI-FPR3myc (which contains a 12-residue 
insert harboring a c-Myc epitope introduced in-frame be- 
tween codons 43 and 44 of the FPR3 coding sequence), 
GALI-FPR3C, or the vector alone, to form single colonies 
on selective medium. When the selective medium contained 
glucose as the carbon source (which represses expression of 
the GAL/promoter), cells grew equally well, regardless of 
the plasmid they contained (Fig. 5 A). In marked contrast, 
when the selective medium contained galactose as the car- 
bon source (which induces high-level expression from the 
GAL/ promoter), cells expressing full-length Fpr3 (either 
the normal protein or the epitope-tagged version) grew ex- 
tremely slowly, whereas growth of the cells expressing 
Fpr3C, or of the control cells carrying the vector alone, was 
unaffected (Fig. 5 A). This phenotype was observed at all 
temperatures xamined, and was no more pronounced at 
elevated (36°C) or reduced (140C) temperatures (data not 
shown). 
To determine if the NH2-terminal domain contributes to 
the toxicity caused by Fpr3 overproduction, a construct was 
made that expresses the epitope-tagged version of the NH~- 
terminal 301 codons of the FPR3 gene under control of the 
GAL/ promoter in the same vector. When otherwise wild- 
type cells harboring either GALI-FPR3, GALI-FPR3C, GALI- 
FPR3Nmyc, or vector alone, were grown on selective me- 
dium with glucose as the carbon source, the efficiency of 
plating of 5-fold serial dilutions of all four strains was essen- 
tially identical (Fig. 5 B). In contrast, when plated on galac- 
tose-containing medium, cells expressing both full-length 
Fpr3 and Fpr3Nmyc plated with at least a 10-100-fold lower 
efficiency than the cells expressing Fpr3C or the vector only 
control (Fig. 5 B). 
Becausefprl mutants are resistant to growth inhibition by 
rapamycin and because overproduction f full-length Fpr3 
did not substitute for Fprl to mediate rapamycin killing, we 
were able to employ an fprl strain background as means to 
determine if the catalytic domain contributes to the toxicity 
caused by Fpr3 overproduction. Binding of rapamycin to the 
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active site of the catalytic domain of Fpr3 would presumably 
preclude its ability to interact with its normal in vivo sub- 
strate(s). When plated on glucose medium, fpr/cel ls  carry- 
ing either GAL1-FPR3, GALI-FPR3C, GALI-FPR3Nmyc, or 
the vector alone, grew equally well (Fig. 6). As observed in 
Figure 5. Overexpression of 
full-length Fpr3 or its NH2- 
terminal domain is toxic. (A) 
Samples of cultures (A~0 m 
= 0.02) of strain YBll2 
(MAlk fprl-2: :ADE2 fpr3-2: : 
HIS3) carrying either vector 
alone, YEP351GAL [Vector), 
or the same plasmid express- 
ing either fifll-length Fpr3, 
pYB123 [FPR3], or a deriva- 
tive of full-length Fpr3 con- 
taining a c-Myc epitope 
inserted in-frame between 
residues 43 and 43, pYBI24 
[FPR3myc), or the COOH- 
terminal domain of Fpr3, 
pYB120 [FPR3C), were spot- 
ted onto plates containing SD- 
Leu medium with either glu- 
cose (Glc) or galactose (Gal) 
as the carbon source and then 
streaked for single colonies. 
(B) Identical initial concen- 
trations of the same strains as 
shown in A, as well as of the 
same strain (YBll2) carrying 
the same vector expressing 
just the NH2-terminal domain 
of Fpr3, pYB126 [FPR3N), 
were spotted on SD-Leu 
plates containing either glu- 
cose (Glc) or galactose (Gal) 
at serial dilutions ranging 
from A600 m = 0.5 (left-mos0 
to A600 nm = 0.001 (right- 
most). 
wild-type cells (data not shown), when the same strains were 
plated on galactose medium, the fprl cells expressing full- 
length Fpr3 or Fpr3Nmyc grew much more poorly than cells 
expressing Fpr3C or the vector only control (Fig. 6). Re- 
markably, however, when the galactose medium contained 
Figure 6. Rapamycin ameliorates the toxicity of Frp3 overproduction. The same strains described in the legend to Fig. 5 were streaked 
to single colonies on plates containing either glucose (Glc) or galactose (Gal) as the carbon source in the absence and presence of the 
indicated concentrations of rapamycin. 
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even low concentrations of rapamycin, the poor growth of 
cells expressing Fpr3 was largely reversed, whereas the poor 
growth of cells expressing Fpr3Nmyc was not spared. (Par- 
tial reversal was observed even at concentrations of rapamy- 
cin, 0.01-0.1 #g/ml, that are below those necessary to see 
growth inhibition mediated by the Fpr3C domain). Taken to- 
gether, these findings indicate that both its COOH-terminal 
catalytic domain and its NH2-terminal charged omain con- 
tribute significantly to the toxic effect of overproduced Fpr3. 
Fpr3 Is Localized to the Nucleolus 
The BLASTP search that revealed striking homology of the 
COOH-terminai 111 residues of Fpr3 to FKBPs also showed 
that the NH2-terminal domain possesses nearly as great a 
degree of homology (36% amino acid sequence identity) 
over nearly as long a region (98 residues) to nucleolin, a 
mammalian protein localized in the nucleolus. This similar- 
ity is largely confined, however, to long Glu-rich tracts found 
in both Fpr3 and nucleolin. Although other known nucleolar 
proteins from both S. cerevisiae, like Nsrl (Lee et al., 1991) 
and mammals, like Noppl40 (Meier and Blobel, 1992), also 
possess long tracts of acidic residues punctuated by shorter 
stretches of basic residues, such strikingly acidic domains 
are also found in other classes of both nuclear and non- 
nuclear proteins. 
To definitively determine the subceUular compartment in 
which Fpr3 resides, polyclonal antisera were raised against 
both the Fpr3N and Fpr3C domains that were expressed in
and purified from bacterial cells, and specific antibodies 
directed against each domain of the protein were further en- 
riched by affinity purification (see Materials and Methods). 
To demonstrate he specificity of these antibodies, extracts 
Figure 7. Immunological de- 
tection of the FPR3 gene prod- 
uct. (A) Strain YB103 (MATa/ 
MATct frp 3-A I : : URA3 /FPR3 ) 
was sporulated, dissected, and 
the four spores (lanes 1-4)of 
one tetrad were incubated at 
30°C on YPD medium for 
4 d. (B) Genomic DNA iso- 
lated from sub-cultures of 
each of the four correspond- 
ing spore clones shown in A 
was digested with HindlII, 
subjected to electrophoresis 
in a 1% agarose gel, blotted o 
a nitrocellulose filter, and hy- 
bridized to a radioactively la- 
beled 2.2-kb genomic fragment 
containing the FPR3 gene, 
which revealed the fragments 
corresponding to the normal 
FPR3 locus (lanes I and 3) and thefpr3-Al::URA3 mutation (lanes 
2 and 4). (C) Cell extracts were prepared from sub-cultures of each 
of the four corresponding spore clones shown in A, fract onated by 
SDS-PAGE in a 10% gel, transferred electrophoretically to  
nitrocellulose filter, and incubated with affinity-purified antibodies 
directed against the NH2-terminus of Fpr3 derived from serum 
1139 (prepared as described in Materials and Methods). Molecular 
weight markers are the same as those described in the legend to 
Fig. 3. 
were prepared from cultures derived from a tetrad of FPR3 + 
andfpr3 null mutant spores (Fig. 7 B). As expected, the anti- 
bodies specifically recognized the Fpr3 gene product be- 
cause they detected a species with an Mr~ of 65 kD that 
was present in the FPR3 ÷ ceils, but was absent in the other- 
wise isogenic fpr3 null mutants (Fig. 7 B). Furthermore, 
ceils carrying multi-copy plasmids expressing FPR3 greatly 
overproduced the 65-kD species (data not shown). Similarly, 
the major 65-kD band normally observed by Coomassie blue 
staining of the material in our particulate nuclear fractions 
was missing when such fractions were prepared from anfpr3 
null mutant and more prominent when prepared from cells 
overexpressing FPR3 from a plasmid (data not shown). 
In our initial experiments, FPR3 and fpr3 haploids (and 
FPR3/FRP3 and fpr3/fpr3 diploids) were fixed, permeabi- 
lized, stained with the anti-Fpr3 antibodies, and examined 
by indirect immunofluorescence. We found that a signal 
could be readily detected in FPR3 + cells, but not in fpr3 
mutants, and that Fpr3 was confined to a portion of the nu- 
cleus (data not shown). These results provided, first, con- 
firmation of the specificity of the antibodies. Second, Fpr3 
could be readily detected even when expressed from its chro- 
mosomai locus, consistent with the fact that Fpr3 was a 
reasonably abundant species in our original nuclear prepara- 
tions. 
To provide greater resolution, however, we also examined 
the localization of Fpr3 in a commercial brand of baker's 
yeast, which has a much larger cell size than our standard 
laboratory strains because it is highly polyploid. Both the 
anti-Fpr3N antibodies (Fig. 8) and the anti-Fpr3C antibodies 
(data not shown) specifically stained the nucleolar region of 
the nucleus in the polyploid cells, which stains very poorly 
with DAPI. Furthermore, in double labeling studies (Fig. 8), 
the Fpr3 staining was completely congruent with that of a 
known and well-characterized yeast nucleolar protein, fibril- 
larin (NOP1 gene product) (Aris and Blobel, 1988; Tollervey 
et al., 1993). Thus, in agreement with the homology of its 
NH2-terminal domain to extended portions of other known 
nucleolar proteins, Fpr3 is likewise localized exclusively in 
the nucleolus. Furthermore, even when rampantly over- 
produced from the GAL/promoter on a multi-copy vector, 
Fpr3 protein was present predominantly in the nucleolus, al- 
though there was a substantial increase in fluorescence 
around the entire nuclear periphery that appeared to repre- 
sent association with the nuclear envelope (data not shown). 
Discussion 
In a search for novel nuclear proteins, we have identified a
new gene, FPR3, which encodes a previously undescribed 
type of FKBP and is the third FKBP identified in S. cere- 
vi iae to date. Unlike the cytoplasmic Fprl (114 residues) 
and the ER-localized Fpr2 (118 residues, after emoval of the 
signal sequence), which consist only of a folded catalytic and 
drug-binding domain (Van Duyne et al., 1991), Fpr3 (413 
residues) is nearly four times longer by virtue of its striking 
NH2-terminal extension. Another unusually large FKBP, 
p59, has been identified recently in mammalian cells. How- 
ever, this molecule is comprised of two tandem repeats of the 
catalytic domain, separated by a spacer sequence (Tai et al., 
1993), and is found in both the cytosol and the nucleoplasm 
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Figure 8. Fpr3 is localized in the nucleolus. Cells of a commercial polyploid strain of baker's yeast (Fleischrnann's) were grown in YPD, 
harvested, fixed, permeabilized, and then incubated simultaneously either with affinity-purified rabbit polyclonal ntibodies directed against 
the NH2-terminus of Fpr3 (derived from antiserum 1139) and a mouse monoclonal ntibody (mAb A66) directed against a known yeast 
nucleolar marker, fibrillarin (NOP1 gene product) (a-c), or with the IgG fraction from preimmune s rum drawn from the rabbit used to 
prepare anti-Fpr3 antiserum 1139 and the mouse anti-fibrillarin monoclonal ntibody (d-f). The rabbit antibodies were then stained using 
FITC-conjugated goat anti-rabbit immunoglobulin (FF/E') and the mouse antibody was stained using Texas Red-conjugated goat anti-mouse 
immunoglobulin (TR). Both sets of cells were counter-stained with DAPI to reveal the position of the chromosomal DNA within the nucleus 
(DAPI). The nucleolus tains relatively poorly with DAPI because of its high RNA and protein content. Bar, 2/zm. 
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(Alnemri et al., 1993). Hence, this mammalian FKBP 
differs in both structure and localization from Fpr3. 
Despite its unusual structure, Fpr3 possesses PPIase activ- 
ity in vitro, and can be inhibited by both rapamycin and 
FKS06. Because the first 60 amino acids of Fpr3 contain 
eight X-Pro bonds (almost as many X-Pro bonds as there are 
in the remainder of the 301-residue NH2-terminal exten- 
sion), it seemed reasonable that the NH~-terminus might 
act as an intramolecular utoinhibitory domain. However, 
we found that the specific activities of purified full-length 
Fpr3 and the isolated COOH-terminal catalytic domain, 
Fpr3C, were virtually indistinguishable within the limits of 
sensitivity of the assay used. As has been observed for other 
FKBPs (Park et al., 1992), Fpr3 promoted a somewhat 
faster ate of isomerization for a substrate containing a Leu- 
Pro bond compared to an otherwise identical substrate with 
an Ala-Pro bond. Members of the other family of PPIases, 
the cyclophilins, display the opposite substrate preference 
(Harrison and Stein, 1990). 
We found that fpr3 null mutations had no discernible 
phenotype. We suspected that, because of its small size (12 
kD), the normally cytosolic FPRI gene product might be 
able to pass through nuclear pores and might, therefore, be 
able to substitute for the loss of Fpr3 function. However, 
even fpr / fpr2 fpr3 triple null mutants had no detectable 
growth defect. If the critical function of FKBPs is related to 
their PPIase activity, it is possible that the cyclophilins may 
serve a redundant, or overlapping, function in cells. Indeed, 
in S. cerevisiae, cyclophilin homologues have been described 
which reside in the cytoplasm (CYP1 gene product), in the 
lumen of the ER (CYF2 gene product), and in the mitochon- 
drion (CYP3 gene product) (Haendler et al., 1989; Koser et 
al., 1991; Davis et al., 1992; McLaughlin et al., 1992). 
Thus, it would not be too surprising if one or more cyclophi- 
lins also were localized in the nucleus and/or the nucleolus, 
which may explain the absence of an obvious phenotype 
when the cell lacks Fpr3. 
If FKBPs and cyclophilins are involved in promoting pro- 
tein folding and protein assembly events in vivo, it might be 
anticipated that in the absence of these functions cells might 
be more sensitive to conditions that place more stress on the 
cells capacity to carry out such processes, for example when 
proteins are caused to unfold by a heat shock or if normal 
folding reactions are slowed down by reducing the tempera- 
ture. Indeed, it has been found that mutations in either of two 
cyclophilin genes, CYP1 or CYP2, reduce the survival of 
yeast cells following a heat shock (Sykes et all, 1993). In 
contrast, we found that f'pr3 mutants are not more sensitive 
to heat shock than their otherwise isogenic ontrols (neither 
were they more cold sensitive). Similarly, it has been 
reported thatfprl null mutants are not more heat shock sensi- 
tive than FPR1 ÷ controls (Sykes et al., 1993). 
Conversely, in the absence of FKBPs and cyclophilins, it
is possible that cells might accumulate higher levels of mis- 
folded proteins and/or aggregated unassembled proteins than 
wild-type cells, which might act as a signal to induce stress 
responses. In fact, consistent with a potential role during 
stress response, transcription of both the CYP1 and CYP2 
genes is modestly induced (two- to threefold) when yeast 
cells are subjected to a heat shock; and the promoters of both 
genes contain sequences that match the consensus heat shock 
response lement (HSE) (Sykes et al., 1993). In contrast, 
transcription of the FPR1 gene is not heat shock-responsive 
(Sykes et al., 1993). Similarly, the 5'-flanking region of the 
FPR3 gene lacks any sequence resembling an HSE. As one 
means to determine if misfolded proteins might be ac- 
cumulating in cells lackingfpr3 function even under normal 
growth conditions, we introduced a reporter plasmid, SSA/- 
lacZ, which contains an HSE and is highly induced upon 
heat shock (Slater and Craig, 1987). We found thatfpr3 mu- 
tants did not display any elevation i  the basal evel of expres- 
sion of the SSAI-IacZ reporter plasmid, compared to i sogenic 
FPR3 + control cells, and did not show any defect in the in- 
duced level of expression of this reporter gene (B. Benton, 
unpublished results). Hence, currently there is no evidence 
that Fpr3, or any of the other FKBPs yet identified in yeast, 
play any role during response to stress. 
One of the most striking features of Fpr3 is its strict sub- 
cellular localization. Using either of two different polyclonal 
antibodies, each directed against a different domain of the 
protein, it was found that Fpr3 resides exclusively in the 
nucleolar egion of the nucleus. The original identification 
of Fpr3 as a major protein in preparations ofisolated nuclei, 
and cell fractionation experiments which have been per- 
formed subsequently (B. Benton, unpublished results), are 
fully consistent with the compartmentation of Fpr3 in the 
nucleolus. Furthermore, these observations uggest hat 
Fpr3 is very tightly associated with other elements in the 
nucleolus because little or no Fpr3 appears to leach out from 
the nuclei during cell lysis and fractionation. Moreover, only 
20% or so of the Fpr3 can be extracted into soluble form 
from isolated nuclei by treatment with high salt (0.5 M NaC1) 
and none is extracted by the non-ionic detergent (1% Triton 
X-100). On the other hand, more chaotropic agents are 
somewhat more efficacious in extracting Fpr3 into the solu- 
ble fraction. For example, when isolated nuclei are treated 
with 0.3 M (NI-L)2SO4, about half of the Fpr3 is released 
into the soluble fraction (B. Benton, unpublished results). 
We also attempted to localize Fpr3 using a derivative in 
which a 12-residue c-Myc epitope-containing tag was in- 
serted between amino acids 43 and 44 in the Fpr3 sequence 
because the cognate anti-c-Myc mAb 9El0 gives little or no 
background staining of yeast cells (see, for example, Kuchler 
et al., 1993). However, even when the corresponding gene 
(FPR3myc) was carried on a low-copy-number (CEN-based) 
plasmid and introduced into strain YB104 (MATa/MATt~- 
fpr3-zXl::URA3/fpr3-AI::URA3), which lacks any endoge- 
nous Fpr3, the c-Myc-tagged Fpr3 was not confined solely 
to the nucleolus, but was found more diffusely throughout 
the nucleus. In most cells, the Fpr3myc olocalized with the 
nuclear DNA, but in some cells it was also observed in small 
vesicle-like bodies in the cytosol. Furthermore, in cells that 
were apparently premitotic because they contained a large 
bud in which the nucleus had migrated from its central loca- 
tion in the mother cell into the bud neck, Fpr3myc was fre- 
quently found within a DNA-less projection that extended 
from the mother cell nucleus into the bud. This kind of struc- 
ture is thought to define an early stage of nuclear migration 
(Davis and Fink, 1990), but it is also reminiscent of the 
"tracks" seen by Meier and Blobel (1992) that appear to Shut- 
tie other nucleolar proteins between the nucleolus and the 
cytoplasm in animal cells. Curiously, when just the NH2 
terminus of the c-Myc-tagged Fpr3 was expressed in yeast 
ceils, this domain of the protein targeted very efficiently and 
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specifically to the nucleolus, just like authentic Fpr3 (Zang, 
1994). Thus, it is not clear why, in the context of full-length 
Fpr3, the presence of the short epitope sequence appears to 
perturb its normal localization. Nonetheless, based on at 
least this case, conclusions about subceUular distribution 
based on an epitope-tagged protein should be interpreted 
with caution. 
Localization of Fpr3 to the nucleolus uggests possible 
roles for this PPIase in the folding of ribosomal proteins or 
rRNA processing enzymes (perhaps during their import into 
this region of the nucleus), in the assembly of preribosomes, 
and/or in the export of ribosomes to the cytoplasm. Most of 
the nucleolar genes believed to be involved in the maturation 
of rRNA or of ribsomes cause a pronounced growth defect 
when mutated. Furthermore, mutations in these genes lead 
to an accumulation of the 35S pre-rRNA precursor, and re- 
sult in a concomitant diminution in the steady-state level of 
the 18S and 25S rRNAs (Woolford and Warner, 1991). How- 
ever, neitherfpr3 null mutants nor normal cells acutely over- 
produce FPR3 from the GAL/promoter on a multi-copy vec- 
tor (a condition that is toxic to the cells) showed any marked 
change in the steady-state level of the 18S and 25S rRNA 
species compared to control cells, although infpr3 mutants 
there is some modest accumulation fthe 35S rRNA precur- 
sor (B. Benton, unpublished results). Thus, Fpr3 appears to 
have a more subtle role in the metabolism of the nucleolus. 
Whether Fpr3 has a specific role in the nucleolus as a con- 
sequence of its localization to this compartment or because 
it has specificity for substrates that are restricted to the 
nucleolus, or both, remains to be determined. There are both 
genetic and biochemical pproaches that can be used to help 
elucidate the function of Fpr3 and to identify its physiologi- 
cally relevant substrates. Because overproduction f Fpr3 is 
toxic to cells, we have been able to select several dosage sup- 
pressors from a cDNA library driven by the GAL/promoter 
(Liu et al., 1992), which rescue this growth inhibition when 
coexpressed with GAL1-FPR3 in the same cell. One of these 
suppressors encodes ribosomal protein L34 (B. Benton and 
J.-H. Zang, unpublished results), for which there are two 
separate genes in the S. cerevisiae genome (Woolford and 
Warner, 1991). We are currently pursuing other approaches 
to determine if the interaction between Fpr3 and L34 is phys- 
iologically meaningful. Furthermore, like certain other 
nucleolar proteins, including nucleolin (with which Fpr3 
shares significant homology in its NH2-terminal domain) 
(Belenguer et al., 1990; Peter et al., 1990), Fpr3 is phos- 
phorylated invivo and the phosphorylation sites are confined 
to the NH2-terminal extension (L. Wilson, B. Benton, J. 
Thorner, and G. S. Martin, manuscript in preparation). 
Whether these modifications have any consequence for the 
activity, regulation, localization or stability of Fpr3 is cur- 
rently under investigation. 
Finally, some of our results may bear on the spatial restric- 
tion of the signal transduction components hat are the tar- 
gets for the growth inhibitory effects of rapamycin-FKBP 
complexes. Since Fpr3 was properly localized to the nucleo- 
lus even when greatly overproduced, yet rapamycin was able 
to reverse the toxic effects of Fpr3 overproduction, rapamy- 
cin can presumably enter the nucleus. In contrast, the 
isolated COOH-terminal domain (Fpr3C) of Fpr3 was a 
cytosolic protein, was not deleterious to growth when over- 
produced, yet was able to mediate the growth inhibitory ac- 
tion of rapamycin in cells lacking Fprl, the major cytosolic 
FKBE Similarly, overproduction f a normally ER-localized 
cyclophilin does not increase the sensitivity of T cells to cy- 
closporin A-mediated inhibition of calcineurin; but, if its 
signal sequence is removed, such that the cyclophilin is now 
overproduced in the cytosol, calcineurin inhibition can be 
achieved at lower doses of cyclosporin A (Brain et al., 1993). 
Therefore, our results uggest, first, that the target(s) of the 
growth inhibitory action of rapamycin-FKBP complexes 
(presumably Tot1 and Tot2) are only accessible from the 
cytoplasm. Since rapamycin binds to the active site of 
FKBPs and inhibits their PPIase activity, the second conclu- 
sion from our observations is that overproduced Fpr3 is toxic 
because it is acting inappropriately on one (or more) of its 
normal substrates oris interacting with an inappropriate sub- 
strate within the nucleolus. Further analysis of the dosage 
suppressors we have isolated may help resolve this latter 
issue. 
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